Inhibition of Protein Aggregation and Endoplasmic Reticulum Stress as a Targeted Therapy for α-Synucleinopathy
Open Access
- 30 July 2023
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (8) , 2051
Abstract
α-synuclein (α-syn) is an intrinsically disordered protein abundant in the central nervous system. Physiologically, the protein regulates vesicle trafficking and neurotransmitter release in the presynaptic terminals. Pathologies related to misfolding and aggregation of α-syn are referred to as α-synucleinopathies, and they constitute a frequent cause of neurodegeneration. The most common α-synucleinopathy, Parkinson’s disease (PD), is caused by abnormal accumulation of α-syn in the dopaminergic neurons of the midbrain. This results in protein overload, activation of endoplasmic reticulum (ER) stress, and, ultimately, neural cell apoptosis and neurodegeneration. To date, the available treatment options for PD are only symptomatic and rely on dopamine replacement therapy or palliative surgery. As the prevalence of PD has skyrocketed in recent years, there is a pending issue for development of new disease-modifying strategies. These include anti-aggregative agents that target α-syn directly (gene therapy, small molecules and immunization), indirectly (modulators of ER stress, oxidative stress and clearance pathways) or combine both actions (natural compounds). Herein, we provide an overview on the characteristic features of the structure and pathogenic mechanisms of α-syn that could be targeted with novel molecular-based therapies.Keywords
Funding Information
- Medical University of Lodz, Poland (503/5-156-07/503-11-001, 2021/43/O/NZ5/02068)
- Narodowe Centrum Nauki (503/5-156-07/503-11-001, 2021/43/O/NZ5/02068)
This publication has 411 references indexed in Scilit:
- Alpha-Synuclein Induces Lysosomal Rupture and Cathepsin Dependent Reactive Oxygen Species Following EndocytosisPLOS ONE, 2013
- Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s diseaseActa Neuropathologica, 2013
- SIRT1 and SIRT2: emerging targets in neurodegenerationEMBO Molecular Medicine, 2013
- Ambroxol as a pharmacological chaperone for mutant glucocerebrosidaseBlood Cells, Molecules, and Diseases, 2013
- Role of C‐terminal negative charges and tyrosine residues in fibril formation of α‐synucleinBrain and Behavior, 2012
- Differential Activation of the ER Stress Factor XBP1 by Oligomeric AssembliesNeurochemical Research, 2012
- Glucocerebrosidase deficiency in substantia nigra of parkinson disease brainsAnnals of Neurology, 2012
- A Novel “Molecular Tweezer” Inhibitor of α-Synuclein Neurotoxicity in Vitro and in VivoNeurotherapeutics, 2012
- Interactions between Hsp70 and the Hydrophobic Core of α-Synuclein Inhibit Fibril AssemblyBiochemistry, 2008
- Isofagomine Induced Stabilization of GlucocerebrosidaseChemBioChem, 2008